Maze Ther­a­peu­tics spins out two new com­pa­nies with Al­loy and Bridge­Bio

The start­up has be­come the starter.

Just un­der two years af­ter burst­ing on­to the scene with close to $200 mil­lion, Maze Ther­a­peu­tics is spin­ning out two new com­pa­nies, fo­cus­ing its hu­man ge­net­ics and func­tion­al ge­nomics plat­form on oph­thal­mol­o­gy and car­dio­vas­cu­lar dis­ease.

The new com­pa­nies — Broad­wing Bio and Con­tour Ther­a­peu­tics — were formed from part­ner­ships with Al­loy Ther­a­peu­tics and Bridge­Bio re­spec­tive­ly. While the com­pa­nies are keep­ing the fi­nan­cial terms un­der wraps, Maze says it has three pro­grams go­ing be­tween the two col­lab­o­ra­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER